Systemic Treatment of Melanoma

Abstract Systemic therapy for melanoma patients has dramatically improved over the past decade. New treatment strategies have significantly ameliorated survival and prognosis of affected patients. The indication for immune directed and targeted therapies has expanded and can be considered for both very early melanoma stages as well as advanced disease. Ongoing challenges deal with reducing development of primary and secondary resistance to antitumoural drugs and identifying useful biomarkers as well as improving quality of life of affected patients. Overall, the aim to cure metastatic melanoma has become more tangible than ever before.